151P Matching-adjusted indirect comparisons (MAICs) of nivolumab + ipilimumab (N + I) vs durvalumab + tremelimumab (D + T) and atezolizumab + bevacizumab (A + B) for first-line (1L) unresectable hepatocellular carcinoma (uHCC) | Publicación